Session: Patient Involvement
It is now generally accepted that patients and
the public have a right to be involved in decisions about the
prioritisation, design, conduct and dissemination of research that
can affect their lives. There are also many published accounts of
how patient and public involvement (PPI) has made important
contributions to clinical trials. Yet many questions remain about
the most effective methods of PPI. This session will focus on the
methodological issues, from the researcher’s perspective, in
involving patients and the public where the goal is to improve the
design and conduct of clinical trials.
Aims
· different models
for PPI in clinical trials and their advantages and
disadvantages
· pptimising PPI to
the diverse needs of different trials
· selecting,
training and sustaining the engagement of PPI representatives
· training and
supporting the clinical trial community in implementing PPI
· methods for
assessing the impact of PPI on clinical trials, including what
outcomes of PPI should be assessed
· methods for
assessing the effectiveness and cost-effectiveness of PPI in
clinical trials
Oral Presentations
Click on the links below to view the presentations.
What have we
learned from a decade of patient involvement in OMERACT and its
effect on trial outcome assessments?
Involvement of
consumers in studies run by the Medical Research Council Clinical
Trials Unit (MRC CTU): results of a survey